| Autor: |
Fischl, Margaret A., Ribaudo, Heather J., Collier, Ann C., Erice, Alejo, Giuliano, Marina, Dehlinger, Marjorie, Eron, Joseph J., Jr., Saag, Michael S., Hammer, Scott M., Vella, Stefano, Morse, Gene D., Feinberg, Judith E. |
| Předmět: |
|
| Zdroj: |
Journal of Infectious Diseases; 9/1/2003, Vol. 188 Issue 5, p625, 10p |
| Abstrakt: |
To compare long-term virologic benefits of antiretroviral regimens in persons with advanced human immunodeficiency virus (HIV) disease, a randomized, open-label study was conducted of 517 subjects with no or limited previous experience with antiretroviral therapy. Subjects received lamivudine plus zidovudine and indinavir (indinavir group), efavirenz plus indinavir (efavirenz + indinavir group), or nelfinavir plus indinavir (nelfinavir + indinavir group) and were monitored for 2.1 years. Virologic failure was lower in the efavirenz + indinavir group (P=.04) and higher in the nelfinavir + indinavir group (P=.006), compared with that in the indinavir group. No difference in grade 3 or 4 adverse event rates in the efavirenz + indinavir group (P=.97) and a trend toward an increased rate in the nelfinavir + indinavir group (P=.07), compared with the indinavir group, were noted. A 4-drug regimen containing efavirenz plus indinavir resulted in a superior virologic response, whereas one containing nelfinavir plus indinavir resulted in an inferior response and a greater likelihood of toxicity. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
